Innate Pharma (IPHA) Receivables (2017 - 2025)
Historic Receivables for Innate Pharma (IPHA) over the last 9 years, with Q2 2025 value amounting to $5.6 million.
- Innate Pharma's Receivables fell 7370.96% to $5.6 million in Q2 2025 from the same period last year, while for Jun 2025 it was $5.6 million, marking a year-over-year decrease of 7370.96%. This contributed to the annual value of $5.4 million for FY2024, which is 9240.89% down from last year.
- Latest data reveals that Innate Pharma reported Receivables of $5.6 million as of Q2 2025, which was down 7370.96% from $5.4 million recorded in Q4 2024.
- Innate Pharma's Receivables' 5-year high stood at $71.2 million during Q4 2023, with a 5-year trough of $5.4 million in Q4 2024.
- Its 5-year average for Receivables is $40.0 million, with a median of $53.6 million in 2022.
- As far as peak fluctuations go, Innate Pharma's Receivables plummeted by 9965.93% in 2021, and later skyrocketed by 14346.12% in 2022.
- Innate Pharma's Receivables (Quarter) stood at $22.0 million in 2021, then surged by 143.46% to $53.6 million in 2022, then skyrocketed by 32.99% to $71.2 million in 2023, then plummeted by 92.41% to $5.4 million in 2024, then rose by 3.63% to $5.6 million in 2025.
- Its Receivables was $5.6 million in Q2 2025, compared to $5.4 million in Q4 2024 and $21.3 million in Q2 2024.